Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafluprost/Timolol Morning vs Evening Dosing in Glaucoma
NCT03612817Phase 4Completed
- Sponsor
- Aristotle University of Thessaloniki
- Start
- Jan 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tafluprost + timolol in open-angle glaucoma (OAG), sponsored by Aristotle University of Thessaloniki. Started Jan 2017; status: completed.
02
Drugs
tafluprost + timolol
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT03612817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03612817.